# EVANIUM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evanium

- Industry: Biotechnology
- Headquarters: Regensburg, Germany
- Website: www.evanium.de
- Total disclosed funding: $2.5M
- Latest round: Seed (Dec 3, 2025)
- Investors on record: 6

## About

Based in Germany, EVANIUM, founded by Felix Rolka and his team, specializes in the development of innovative health ingredients utilizing proprietary technology to enhance natural product efficacy across various sectors.Founded in 2019, EVANIUM operates in Regensburg, Germany, focusing on the development of advanced health ingredients. The company has successfully completed 2 deals to date. The latest funding round was a Seed round, in which EVANIUM raised EUR 2.2 million, led by Foodlabs in December 2025, bringing the total amount raised to EUR 2.2 million. David Ofner, Felix Rolka, and Felix Werkmann are among the founders of the company.EVANIUM specializes in the development of innovative health ingredients based on secondary plant compounds, leveraging its proprietary OPTISOLV® Technology. The company focuses on bioactive flavonoids and polyphenols, enhancing their effectiveness for applications in nutraceuticals, cosmetics, functional foods, and pharmaceuticals. Key ingredients include OPTISOLV® Berberine, OPTISOLV® Boswellia, OPTISOLV® Passiflora, and OPTISOLV® Curcumin, targeting improved bioavailability for better product performance. EVANIUM serves clients primarily in Europe across the food, personal care, and pharmaceutical industries.EVANIUM's revenue model is based on B2B partnerships with manufacturers and brands in food, cosmetic, and pharmaceutical sectors. The company generates revenue through the sale of its proprietary ingredients, with pricing determined by the added value from enhanced bioavailability and stability. Transactions typically occur through negotiated contracts based on volume and exclusivity tailored to client needs.In December 2025, EVANIUM secured EUR 2.2 million in Seed funding, led by Foodlabs, with additional participation from Feast Ventures, Denava Ag, VMCIV GmbH, HUTEC Beteiligungen GmbH, and acmaios GmbH. This funding will be utilized to scale the OPTISOLV drug delivery technology, expand the product portfolio in nutraceuticals, nutricosmetics, and functional foods, advance clinical studies, grow the team, and accelerate international market expansion.

## Funding rounds

- Seed, Dec 3, 2025, $2.5M — Foodlabs, Denava Ag, Feast Ventures, acmaios GmbH, VMCIV GmbH, HUTEC Beteiligungen GmbH

## Investors

- Foodlabs (https://capitalatlas.ai/funds/foodlabs) — Seed
- Denava Ag — Seed
- Feast Ventures (https://capitalatlas.ai/funds/feast-ventures) — Seed
- acmaios GmbH — Seed
- VMCIV GmbH — Seed
- HUTEC Beteiligungen GmbH — Seed